Clinical Trial Update: Phase 2 Study to Evaluate ALN-TTRSC (Revusiran) in Patients With Transthyretin (TTR) Cardiac Amyloidosis [Phase 2]

View source ↗

Summary

Phase 2 study evaluating ALN-TTRSC (Revusiran) in patients with transthyretin cardiac amyloidosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transthyretin Cardiac Amyloidosis

Drugs mentioned

• ALN-TTRSC (Revusiran) (Revusiran)

Snippet

Sponsor: Alnylam Pharmaceuticals | Conditions: TTR-mediated Amyloidosis | Phase 2 | Status: COMPLETED